Sanchine三精品牌怎么样 申请店铺

我要投票 Sanchine三精在补钙行业中的票数:360 更新时间:2025-05-23
Sanchine三精是哪个国家的品牌?「Sanchine三精」是 哈药集团三精制药有限公司 旗下著名品牌。该品牌发源于黑龙江,由创始人芦传有在2015期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力Sanchine三精品牌出海!将品牌入驻外推网,定制Sanchine三精品牌推广信息,可以显著提高Sanchine三精产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

Sanchine三精怎么样

三精制药始建于1950年,初期以生产肌肉和静脉水针剂为主,是黑龙江省最早的专业化生产水针剂和国内最早引进国外水针剂一连机生产设备的企业,是最早通过国家GMP认证的医药企业之一。公司现总占地面积110万平方米,员工总数近6000人,是以OTC产品、处方药与保健食品为主、医药原料和制剂并重的综合性制药企业。2004年,“三精”品牌被国家工商总局认定为“驰名保护”。2011年5月13日,“三精”品牌在“2011中国最有价值品牌评价”中,经权威机构认定,品牌价值为68.93亿元人民币。

目前,三精制药拥有下属子公司15家,其中工业子公司8家、商业子公司5家、其他相关产业子公司2家。截至目前,公司口服液、口服溶液剂、小容量注射剂(非最终灭菌)、冻干粉针剂、片剂、粉针剂、胶囊剂、颗粒剂、合剂、糖浆剂、洗剂、茶剂、散剂13个剂型及无菌原料药(磷霉素钠、炎琥宁)、原料药(拉西地平、盐酸罗沙替丁醋酸酯)均通过2010版GMP认证。其中,口服液剂型产品年生产能力达16亿支。公司主导产品包括葡萄糖酸钙口服溶液、葡萄糖酸锌口服液、双黄连口服液、司乐平片等。近年来,通过药品、保健品的新产品立项研发,不断完善产品线,丰富产品阵容。

六十余年的制药经验,先进的技术设备,一流的管理手段,完善的科研开发体系,使“三精”牌在国内外丰享盛誉。三精一直将产品和服务视为核心竞争力,同时高度重视产品的研发,2004年建成较具规模的研发中心,已成为黑龙江省药物制剂工程技术研究中心、黑龙江省西药制剂重点实验室,承担“十一五”“重大新药创制”科技重大专项——“新型口服缓控释制剂及工艺技术平台”课题和“十二五”“重大新药创制”科技重大专项——“抗阿尔茨海默病药重酒石酸卡巴拉汀及其胶囊的研究开发”课题。2008年,公司成为“国家首批创新型企业”,2012年入选国家火炬计划重点高新技术企业。公司还先后荣获了全国质量管理先进企业、全国守合同重信用企业、全国医药系统优秀企业、全国“五·一劳动奖状”先进集体、“全国企业文化优秀成果奖”、“全国医药行业药品质量诚信建设示范企业”、“21315国际质量信用AAA++级”、“中国优秀诚信企业”、“中国化学制药行业工业企业综合实力百强”企业、黑龙江省“科技创新优秀企业奖”等荣誉称号。

Sanjing pharmaceutical was founded in 1950. At the early stage, it mainly produces muscle and intravenous water injection. It is the first professional enterprise in Heilongjiang Province to produce water injection and the first enterprise in China to introduce foreign water injection production equipment. It is also one of the first pharmaceutical enterprises to pass the national GMP certification. The company now covers an area of 1.1 million square meters and employs nearly 6000 people. It is a comprehensive pharmaceutical enterprise focusing on OTC products, prescription drugs and health food, with equal emphasis on pharmaceutical raw materials and preparations. In 2004, "three fine" brand was recognized as "well-known protection" by the State Administration for Industry and commerce. On May 13, 2011, in the "2011 China's most valuable brand evaluation", the brand value of "three fine" was recognized by the authority as RMB 6.893 billion. At present, Sanjing pharmaceutical has 15 subsidiaries, including 8 Industrial subsidiaries, 5 Commercial subsidiaries and 2 other related industrial subsidiaries. Up to now, 13 dosage forms of the company's oral liquid, oral solution, small volume injection (non final sterilization), freeze-dried powder injection, tablet, powder injection, capsule, granule, mixture, syrup, lotion, tea, powder, sterile API (fosfomycin sodium, Yanhuning), API (lacidipine, rosattidine hydrochloride acetate) have passed GMP certification of 2010 version. Among them, the annual production capacity of oral liquid dosage products reached 1.6 billion. The company's leading products include calcium gluconate oral solution, zinc gluconate oral solution, Shuanghuanglian oral solution, and silepin tablets. In recent years, through the research and development of new products of drugs and health products, the product line has been continuously improved and the product lineup has been enriched. With more than 60 years of pharmaceutical experience, advanced technology and equipment, first-class management means, and perfect scientific research and development system, the "three refined" brand enjoys a good reputation at home and abroad. Sanjing has always regarded products and services as its core competitiveness, and attached great importance to product research and development. In 2004, it established a relatively large-scale research and development center, which has become Heilongjiang pharmaceutical engineering and technology research center and Heilongjiang western pharmaceutical Key Laboratory, undertaking the major science and technology project of "11th Five Year plan" and "major new drug creation" -- new oral sustained and controlled release preparations and technology "Platform" project and "12th Five Year Plan" science and technology major project of "major new drug creation" - research and development of anti Alzheimer's disease drug kabalatin tartrate and its capsule ". In 2008, the company became "the first batch of national innovative enterprises", and in 2012, it was selected as a key high-tech enterprise in the national torch plan. The company has also won the national advanced quality management enterprise, the national contract abiding and trustworthy enterprise, the national excellent pharmaceutical system enterprise, the national advanced collective of "May 1st Labor Award", "national enterprise culture excellent achievement award", "national pharmaceutical industry pharmaceutical quality and integrity construction demonstration enterprise", "21315 International quality and credit AAA + + level", "China excellent and integrity enterprise" "Top 100 enterprises with comprehensive strength in China's chemical and pharmaceutical industry" and "science and technology innovation excellent enterprise award" of Heilongjiang Province, etc.

本文链接: https://brand.waitui.com/41c6b1011.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

宏创控股:拟购买宏拓实业100%股权

36氪获悉,宏创控股公告,公司拟发行股份购买山东魏桥铝电有限公司等九名交易对方持有的山东宏拓实业有限公司100%股权,交易作价为635.18亿元。交易完成后,宏创控股将持有宏拓实业100%股权。本次交易构成关联交易,尚需履行决策和审批程序。

10分钟前

美股科技股盘前涨跌不一,特斯拉跌超1%。

36氪获悉,美股科技股盘前涨跌不一,截至发稿,特斯拉跌超1%,Arm跌近1%,苹果跌0.39%,微软跌0.09%,奈飞跌0.04%;谷歌涨超1%,亚马逊涨0.2%,英伟达涨0.1%,Meta涨0.03%。

10分钟前

热门中概股美股盘前多数走弱,小鹏汽车跌超5%

36氪获悉,热门中概股美股盘前多数走弱,小鹏汽车跌超5%,B站跌超2%,阿里巴巴、网易、理想汽车跌超1%,蔚来跌0.77%,腾讯音乐跌0.53%,拼多多跌0.17%;微博涨超2%。

10分钟前

小米YU 7零百加速3.23s,标准版续航达835公里

36氪获悉,小米YU 7今日正式发布,搭载小米超级电机V6s Plus, 最大马力可达690PS。 0-100km/h 加速3.23s,最高时速253km/h, 100-0km/h 最短制动距离33.9m。小米YU7共有三个版本——单电机后驱的小米YU7,双电机四驱的小米YU7 Pro和最高性能的小米YU7 Max,标准版续航达835公里。

10分钟前

德迈仕:公司控制权拟变更,实控人将变为潘异

36氪获悉,德迈仕公告,公司直接控股股东德迈仕投资的全体股东拟向苏州汇心创智投资有限公司转让德迈仕投资100%的股权,交易价格6.69亿元。如交易事项最终实施,公司直接控股股东不变,汇心创智将通过控制德迈仕投资成为公司间接控股股东,公司实控人由何建平变更为潘异。

10分钟前

本页详细列出关于Sanchine三精的品牌信息,含品牌所属公司介绍,Sanchine三精所处行业的品牌地位及优势。
咨询